Konishi N, Nakaoka S, Tsuzuki T, Matsumoto K, Kitahori Y, Hiasa Y, Urano T, Shiku H
Department of Pathology, Nara Medical University.
Jpn J Cancer Res. 1993 Oct;84(10):1050-4. doi: 10.1111/j.1349-7006.1993.tb02800.x.
The nm23 gene products/nucleoside diphosphate (NDP) kinase expression in prostate carcinomas and benign hyperplasias was evaluated immunohistochemically. Monoclonal antibodies against nm23-H1 and nm23-H2 proteins were prepared using the corresponding proteins fused with glutathione S-transferase as immunogens. Of the 80 cases of nonmetastatic prostate carcinoma examined, 74% (59/80) and 60% (48/80) were immunoreactive for nm23-H1 or nm23-H2 protein, respectively. Negative staining for nm23-H1 occurred in 83% of metastatic lesions, while 34% were negative for nm23-H2. All primary tumors corresponding to the metastases examined showed positive immunostaining for nm23-H1, indicating an inverse relationship between expression of this protein and metastatic status. nm23-H2 protein was detected in 83% of primary tumors and its expression appeared to be significantly correlated to the degree of histological differentiation. In contrast, all cases of benign prostatic hyperplasia showed elevated levels of both nm23-H1 and nm23-H2 expression. These data suggest that the nm23/NDP kinase may play a role in suppressing the expression of malignant potential in prostate carcinomas.
采用免疫组织化学方法评估nm23基因产物/核苷二磷酸（NDP）激酶在前列腺癌和良性增生中的表达。以与谷胱甘肽S-转移酶融合的相应蛋白质作为免疫原，制备抗nm23-H1和nm23-H2蛋白的单克隆抗体。在80例接受检查的非转移性前列腺癌病例中，分别有74%（59/80）和60%（48/80）对nm23-H1或nm23-H2蛋白呈免疫反应性。在83%的转移病灶中nm23-H1染色阴性，而34%的nm23-H2染色阴性。与所检查转移灶对应的所有原发性肿瘤对nm23-H1均呈阳性免疫染色，表明该蛋白的表达与转移状态呈负相关。在83%的原发性肿瘤中检测到nm23-H2蛋白，其表达似乎与组织学分化程度显著相关。相比之下，所有良性前列腺增生病例中nm23-H1和nm23-H2的表达水平均升高。这些数据表明，nm23/NDP激酶可能在抑制前列腺癌恶性潜能的表达中发挥作用。
